Nephron Pharmaceuticals Recalls 2.1 Million Doses of Medicine, Medical Equipment
Nephron Pharmaceuticals recalls 2.1 million doses of medicine and medical equipment because of a lack of assurance of sterility.
By - According to the FDA’s enforcement report, Nephron Sterile Compounding Center, in Columbia, South Carolina, is recalling 2,158,351 medical products including syringes and bags because of a lack of assurance of sterility.
The nationwide recall began on May 18, 2022, and some recalled products listed in the report include the following:
- 8.4% sodium bicarbonate injection
- calcium gluconate injection
- epinephrine injection
- glycopyrrolate injection
- hydromorphone HCl injection
- ketamine hydrochloride injection
- labetalol HCl injection
- lidocaine HCl injection
- neostigmine methylsulfate injection
- oxytocin 30 units/500 mL
- phenylephrine HCl injection
- rocuronium bromide injection
- succinylcholine chloride injection
“Out of an abundance of caution, Nephron is proactively cooperating with the Food and Drug Administration on a voluntary recall of a limited number of product lots. We do not take this lightly,” said Lou Kennedy, owner and CEO of Nephron Pharmaceuticals Corporation.
“While there has been no impact to patient safety, and there is no evidence of contamination, Nephron has decided in the interest of patients to proceed with this recall process.”
“The company is prepared to provide the resources and information necessary to healthcare providers and patients to make certain they have anything they need and any questions answered. They remain our top priority,” Kennedy explained in an issued statement to WIS News.
